Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models.

The therapeutic effect of pterosin A, a small-molecular-weight natural product, on diabetes was investigated. Pterosin A, administered orally for 4 weeks, effectively improved hyperglycemia and glucose intolerance in streptozotocin, high-fat diet-fed, and db/db diabetic mice. There were no adverse effects in normal or diabetic mice treated with pterosin A for 4 weeks. Pterosin A significantly reversed the increased serum insulin and insulin resistance (IR) in dexamethasone-IR mice and in db/db mice. Pterosin A significantly reversed the reduced muscle GLUT-4 translocation and the increased liver phosphoenolpyruvate carboxyl kinase (PEPCK) expression in diabetic mice. Pterosin A also significantly reversed the decreased phosphorylations of AMP-activated protein kinase (AMPK) and Akt in muscles of diabetic mice. The decreased AMPK phosphorylation and increased p38 phosphorylation in livers of db/db mice were effectively reversed by pterosin A. Pterosin A enhanced glucose uptake and AMPK phosphorylation in cultured human muscle cells. In cultured liver cells, pterosin A inhibited inducer-enhanced PEPCK expression, triggered the phosphorylations of AMPK, acetyl CoA carboxylase, and glycogen synthase kinase-3, decreased glycogen synthase phosphorylation, and increased the intracellular glycogen level. These findings indicate that pterosin A may be a potential therapeutic option for diabetes.
AuthorsFeng-Lin Hsu, Chun-Fa Huang, Ya-Wen Chen, Yuan-Peng Yen, Cheng-Tien Wu, Biing-Jiun Uang, Rong-Sen Yang, Shing-Hwa Liu
JournalDiabetes (Diabetes) Vol. 62 Issue 2 Pg. 628-38 (Feb 2013) ISSN: 1939-327X [Electronic] United States
PMID23069626 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biological Products
  • Glucose Transporter Type 4
  • Indans
  • Insulin
  • Sesquiterpenes
  • Slc2a4 protein, mouse
  • pterosin
  • Dexamethasone
  • Glucose
  • Animals
  • Biological Products (therapeutic use)
  • Biological Transport (drug effects)
  • Cells, Cultured
  • Dexamethasone (adverse effects)
  • Diabetes Mellitus, Experimental (drug therapy)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Disease Models, Animal
  • Glucose (metabolism)
  • Glucose Intolerance (drug therapy)
  • Glucose Transporter Type 4 (metabolism)
  • Humans
  • Hyperglycemia (drug therapy)
  • Indans (therapeutic use)
  • Insulin (blood)
  • Insulin Resistance (physiology)
  • Liver (enzymology)
  • Male
  • Mice
  • Muscle, Skeletal (drug effects)
  • Sesquiterpenes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: